The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250033, China.
The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China.
Anal Cell Pathol (Amst). 2020 Nov 25;2020:8396023. doi: 10.1155/2020/8396023. eCollection 2020.
Breast cancer is the leading cause of females characterized by high invasive potential. It is necessary to explore the underlying mechanism of breast cancer metastases and to find specific therapeutic targets. PKM2 is considered a new biomarker of cancer with upregulated expression in tumor tissue. PKM2 participates in the cancer-specific Warburg effect to regulate fast glucose intake consumption. Besides, PKM2 also contributes to cancer progression, especially tumor metastasis. In this study, we showed that PKM2 is upregulated in breast cancer tissues and the upregulating of PKM2 in breast cancer correlates with poor prognosis. PKM2 can regulate tumor progression by promoting tumor cell viability and mobility. Furthermore, overexpression of PKM2 can promote EMT to encourage tumor metastasis. These findings indicate PKM2 is a potentially useful diagnostic biomarker and therapeutic target in breast cancer.
乳腺癌是女性的主要致病原因,其具有高侵袭性。有必要探索乳腺癌转移的潜在机制,并寻找特定的治疗靶点。PKM2 被认为是一种新型的癌症生物标志物,在肿瘤组织中表达上调。PKM2 参与肿瘤特异性的 Warburg 效应,以调节快速葡萄糖摄取消耗。此外,PKM2 还促进癌症进展,特别是肿瘤转移。在本研究中,我们表明 PKM2 在乳腺癌组织中上调,PKM2 在乳腺癌中的上调与预后不良相关。PKM2 可以通过促进肿瘤细胞活力和迁移来调节肿瘤进展。此外,PKM2 的过表达可以促进 EMT,从而促进肿瘤转移。这些发现表明 PKM2 是乳腺癌中一种潜在有用的诊断生物标志物和治疗靶点。